Clinical data
Routes of
Legal status
Legal status
  • Investigational
CAS Number 359625-79-9
PubChem (CID) 9799284
ChemSpider 7975049
Chemical and physical data
Formula C22H23F2N2O2
Molar mass 366.428623 g/mol

MIN-101 (former developmental code names CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia.[1][2][3][4] One of its metabolites also has some affinity for the H1 receptor.[2] As of August 2015, the drug is in phase II clinical trials.[5]

See also


  1. Mestre, Tiago A; Zurowski, Mateusz; Fox, Susan H (2013). "5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders". Expert Opinion on Investigational Drugs. 22 (4): 411–421. doi:10.1517/13543784.2013.769957. ISSN 1354-3784.
  2. 1 2 Ebdrup, Bjørn H; Rasmussen, Hans; Arnt, Jørn; Glenthøj, Birte (2011). "Serotonin 2A receptor antagonists for treatment of schizophrenia". Expert Opinion on Investigational Drugs. 20 (9): 1211–1223. doi:10.1517/13543784.2011.601738. ISSN 1354-3784.
  3. Köster, Luisa-Sophie; Carbon, Maren; Correll, Christoph U (2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs. 19 (4): 511–531. doi:10.1517/14728214.2014.958148. ISSN 1472-8214.
  4. "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
  5. MIN 101

This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.